Additionally, two clinical trials have generated early, but promising, data that inhibition of COX-2 can benefit patients with biochemical recurrence of prostate cancer (i.e., the same transcription factor can regulate increasing PSA levels, but no clinical evidence of disease following androgen-ablation therapy). The gene discussed is PTGS2; the disease is prostate carcinoma.